Physician profile
Michael R Aaron
NPI 1336129071
$41,118.77
in general payments reported to CMS, 2019-2025
40 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $5,985 · 2021: $13K · 2022: $4,689 · 2023: $2,195 · 2024: $2,412 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,274.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $17,664.23 | 2020-2025 | Nexletol |
| Pfizer INC. | $9,105.49 | 2019-2025 | |
| Amgen INC. | $5,094.69 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,906.55 | 2019-2025 | |
| Abbott Laboratories | $1,287.74 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Diamondback Peripheral |
| E.R. Squibb & Sons, L.L.C. | $1,267.95 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $1,014.94 | 2019-2025 | Wainua, Brilinta, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $567.81 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $520.48 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $410.71 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $346.37 | 2019-2025 | Watchman Flx, Watchman Access System |
| Amarin Pharma, INC. | $251.13 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $192.90 | 2021-2023 | Verquvo |
| Cvrx, INC. | $168.11 | 2023 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $166.56 | 2019-2025 | Onpattro, Amvuttra |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Aaron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.